ClouDr Group (HKSE:09955) ROCE % : -17.38% (As of Dec. 2023)

View and export this data going back to 2022. Start your Free Trial

What is ClouDr Group ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. ClouDr Group's annualized ROCE % for the quarter that ended in Dec. 2023 was -17.38%.

ClouDr Group ROCE % Historical Data

The historical data trend for ClouDr Group's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ClouDr Group ROCE % Chart

ClouDr Group Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

-16.51

ClouDr Group Semi-Annual Data
	Dec19	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
ROCE %	Get a 7-Day Free Trial			-	-	-	-16.00	-17.38

ClouDr Group ROCE % Calculation

ClouDr Group's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-346.229	/	( ( (3165.247 - 987.195)	+	(3221.25 - 1204.761) )	/ 2 )
	=	-346.229	/	( (2178.052	+	2016.489)	/ 2 )
	=	-346.229	/	2097.2705
	=	-16.51 %

ClouDr Group's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	-353.78	/	( ( (3066.846 - 1011.967)	+	(3221.25 - 1204.761) )	/ 2 )
	=	-353.78	/	( ( 2054.879	+	2016.489 )	/ 2 )
	=	-353.78	/	2035.684
	=	-17.38 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2023) EBIT data.

ClouDr Group (HKSE:09955) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

ClouDr Group ROCE % Related Terms

Thank you for viewing the detailed overview of ClouDr Group's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

ClouDr Group (HKSE:09955) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » ClouDr Group Ltd (HKSE:09955) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

H3L:Germany

Address

No. 998 Wenyi West Road (Haichuang Yuan), Wuchang Street, Rooms 501, 5th Floor, Building 12, Yuhang District, Zhejiang Province, Hangzhou, CHN

Website

https://www.cloudr.cn

ClouDr Group Ltd provides supplies and SaaS to hospitals and pharmacies, digital marketing services to pharmaceutical companies, and online consultation and prescriptions to patients, all centered around chronic condition management. Its offerings include in-hospital solutions, pharmacy solutions, and individual chronic condition management solutions. The company's in-hospital solution consists of sales of medical devices, consumables and pharmaceuticals, hospital SaaS, and digital marketing services to pharmaceutical companies. It generates revenues from sales of hospital and pharmacy supplies and individual chronic condition management products.

ClouDr Group (HKSE:09955) Headlines

No Headlines